Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  L'Episcopo, Francesca ^a   Tirolo, Cataldo ^a   Caniglia, Salvatore ^a   Testa, Nunzio ^a   Serra, Pier A ^b   Impagnatiello, Francesco ^c   Morale, Maria C ^a   Marchetti, Bianca ^a,d,e  

^a OASI RESEARCH INSTITUTE IRCCS   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c NicOx Research Institute   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROTYROSINE; CELL ANTIGEN; DOPAMINE TRANSPORTER; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; INDUCIBLE NITRIC OXIDE SYNTHASE; MACROPHAGE ANTIGEN 1; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 3-NITROTYROSINE; CD11B ANTIGEN; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; NOS2 PROTEIN, MOUSE; OXIDOREDUCTASE; TYROSINE;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; GENE EXPRESSION; GLIA CELL; IMMUNOBLOTTING; MALE; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; STAINING; STEREOLOGY; SYNAPTIC TRANSMISSION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; HUMAN; IMMUNOLOGY; INFLAMMATION; INTOXICATION; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; ROTAROD TEST; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; FLURBIPROFEN; HUMANS; INFLAMMATION; MACROPHAGE-1 ANTIGEN; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDOREDUCTASES; PARKINSON DISEASE; ROTAROD PERFORMANCE TEST; SUBSTANTIA NIGRA; TYROSINE;

EID: 78549263421     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-83     Document Type: Article

References (104)

1. Tedroff JM. Functional consequences of dopaminergic degeneration in Parkinson's disease. Adv Neurol 1999, 80:67-70.
2. Rascol O, Payoux P, Ory F, Ferriera JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson's disease therapy. Ann Neurol 2003, 53(Suppl 3):S3-12. 10.1002/ana.10513, 12666094.
3. Warner TT, Schapira AHV. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003, 53:S16-S25. 10.1002/ana.10487, 12666095.
4. Hindle JV. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010, 39:156-161. 10.1093/ageing/afp223, 20051606.
5. McGeer P, McGeer E. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004, 10:S3-7. 10.1016/j.parkreldis.2004.01.005, 15109580.
6. Chen H, Zhang SM, Herman MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE. Non steroidal anti-inflammatory drugs and the risk of Parkinson's disease. Arch Neurol 2003, 60:1059-64. 10.1001/archneur.60.8.1059, 12925360.
7. Chen H, Jacobs EJ, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk forParkinson's disease. Ann of Neurol 2005, 58:963-967.
8. Morale MC, Serra PA, Delogu MR, Migheli R, Rocchitta G, Tirolo C, Caniglia S, Testa N, L'Episcopo F, Gennuso F, Scoto GM, Barden N, Miele E, Desole MS, Marchetti B. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. The FASEB Journal 2004, 18:164-166.
9. Marchetti B, Kettenmann H, Streit WJ. Glia-Neuron Crosstalk in Neuroinflammation, Neurodegeneration and Neuroprotection. Brain Res Review Special Issue 2005, 482:129-489.
10. Marchetti B, Serra PA, L'Episcopo F, Tirolo C, Caniglia S, Testa N, Cioni S, Gennuso F, Rocchitta G, Desole MS, Mazzarino MC, Miele E, Morale MC. Hormones are key actors in gene × environment interactions programming the vulnerability to Parkinson's disease: Glia as a common final pathway. Ann NY Acad Sci 2005, 1057:296-318. 10.1196/annals.1356.023, 16399902.
11. Marchetti B, Serra PA, Tirolo C, L'Episcopo F, Caniglia S, Gennuso F, Testa N, Miele E, Desole MS, Barden N, Morale MC. Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental Parkinsonism: pivotal role for glia-neuron interactions. Brain Res Reviews 2005, 48:302-321.
12. Morale MC, L'Episcopo F, Tirolo C, Giaquinta G, Caniglia S, Testa N, Arcieri P, Serra PA, Lupo G, Alberghina M, Harada N, Honda S, Panzica GC, Marchetti B. Loss of Aromatase Cytochrome P450 function as a risk factor for Parkinson's disease?. Brain Res Rev 2008, 57:431-443. 10.1016/j.brainresrev.2007.10.011, 18063054.
13. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397. 10.1016/S1474-4422(09)70062-6, 19296921.
14. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008, 29:357-65. 10.1016/j.it.2008.05.002, 18599350.
15. Przedborski S. Inflammation and Parkinson's disease pathogenesis. Mov disord 2010, 25(Suppl 1):S55-7. 10.1002/mds.22638, 20187228.
16. Hoang T, Choi DK, Nagai M, Wu DC, Nagata T, Prou D, Wilson GL, Vila M, Jackson-Lewis V, Dawson V, Dawson TM, Chesselet MF, Przedborski S. Neuronal NOS and ciyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson's Disease. Free Radical Biology & Medicine 2009, 47:1049-1056.
17. Boger HA, Granholm AC, McGinty JF, Middaugh LD. A dual-hit animal model for age-related parkinsonism. Prog in Neurobiol 2010, 90:217-229.
18. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B. Glia as a turning point in the therapeutic strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 2010, 9:349-72.
19. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-91.
20. Langston JW, Forno LS, Tetrud J, Reevers AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605. 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F, 10514096.
21. Kurkowska-Jastrzebska I, Wrońska A, Kohutnicka M, Członkowski A, Członkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156:50-61. 10.1006/exnr.1998.6993, 10192776.
22. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 2004, 24:395-401.
23. McGeer P, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008, 23:474-83. 10.1002/mds.21751, 18044695.
24. Marchetti B, Abbracchio MP. To be or not to be (inflamed) is that the question in anti-inflammatory drug therapy of neurodegenerative diseases?. Trends in Pharmacological Sci 2005, 26:517-525.
25. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Brit J Pharmacol 2007, 150:963-976.
26. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010, 37:510-8. 10.1016/j.nbd.2009.11.004, 19913097.
27. Liberatore GT, Jacksons-Lewis V, Vukosavic C, Mandir AS, Vila M, McAuliffe WG. Inducibile nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat Med 1999, 5:1403-1409. 10.1038/70978, 10581083.
28. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci 2002, 22:1763-71.
29. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Blocl ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. Aggragated alpha synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005, 19:533-542. 10.1096/fj.04-2751com, 15791003.
30. Zhang W, Dallas S, Zhang D, Guo JP, Pang H, Wilson B. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant Alpha-Synuclein. Glia 2007, 55:1178-1188. 10.1002/glia.20532, 17600340.
31. Purisai MG, McCormack AL, Cumine S, Li J, Isla MZ, Di Monte D. Microglial activation is a priming event leading tom paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 2007, 25:392-400. 10.1016/j.nbd.2006.10.008, 2001246, 17166727.
32. Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol 2008, 181:7194-7204. 2759089, 18981141.
33. Mander P, Brown G. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual key mechanism of inflammatory degeneration. J Neuroinflammation 2005, 2:20-27. 10.1186/1742-2094-2-20, 1232863, 16156895.
34. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000, 74:2213-6. 10.1046/j.1471-4159.2000.0742213.x, 10800968.
35. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002, 110:49-58. 10.1016/S0306-4522(01)00562-0, 11882372.
36. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales K, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in MPTP model of Parkinson's disease. Proc Natl Acad Sci 2001, 98:14669-14674. 10.1073/pnas.251341998, 64739, 11724929.
37. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001, 39:167-74. 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U, 11180504.
38. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci 2003, 100:5473-5478. 10.1073/pnas.0837397100, 154369, 12702778.
39. Kurkowska-Jastrzebska I, Babiuch M, Joniec I, Przybyłkowski A, Członkowski A, Członkowska A. Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol 2002, 2:1213-8. 10.1016/S1567-5769(02)00078-4, 12349958.
40. Kurkowska-Jastrzebska I, Litwin T, Joniec I, Ciesielska A, Przybyłkowski A, Członkowski A, Członkowska A. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int Immunopharmacol 2004, 4:1307-18. 10.1016/j.intimp.2004.05.006, 15313429.
41. Kurkowska-Jjastrezba I, Członkowski A, Członkowska A. Ibuprofen and the mouse model of Parkinson's disease. Ann Neurol 2006, 59:988-9.
42. Vijitruth R, Liu M, Choi DY, Nguyen XB, Hunter RL, Bing G. Ciclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model Parkinson's disease. J Neuroinflammation 2006, 3:6. 10.1186/1742-2094-3-6, 1440849, 16566823.
43. Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O. Selective COX2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 2004, 1:6-16. 10.1186/1742-2094-1-6, 483059, 15285796.
44. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 2003, 966:245-52. 10.1016/S0006-8993(02)04174-4, 12618347.
45. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurology 2007, 205:295-312.
46. Asanuma M, Miyazaki I. Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?. Exp Neurology 2007, 206:172-178.
47. Asanuma M, Miyazaki I. Non-steroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation. Expert Rev Neurotherapeutics 2006, 6:1313-1325.
48. Asanuma M, Miyazaki I, Kohno M, Ogawa N. Neuroprotective effects on non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 2001, 76:1895-1904. 10.1046/j.1471-4159.2001.00205.x, 11259508.
49. Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009, 26:769-779. 10.2165/11316780-000000000-00000, 19728750.
50. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson's disease: a meta-analysis. Neurology 2010, 74:995-1002. 10.1212/WNL.0b013e3181d5a4a3, 20308684.
51. Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2005, 2:355-65. 10.2174/1567205054367883, 15974901.
52. Klegeris A, McGeer EG, McGeer PL. Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 2007, 20:351-7. 10.1097/WCO.0b013e3280adc943, 17495632.
53. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004, 63:901-10.
54. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev 2005, 48:352-9. 10.1016/j.brainresrev.2004.12.024, 15850674.
55. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol Suppl 1997, 49:6-8.
56. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008, 11:81s-110s.
57. Wallace B, Reuter C, Cicala W, McKnight MB, Grisham G, Cirino A. Diclofenac derivative without ulcerogenic properties. J Pharmacol 1994, 257:249-255.
58. Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of NO releasing aspirin. Nat Rev Drug Disc 2002, 1:375-382.
59. Fiorucci S, Antonelli E, Santucci L, Morelli O, Miglietti M, Federici B. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 1999, 116:1089-1106. 10.1016/S0016-5085(99)70012-0, 10220501.
60. Fiorucci S, Antonelli E. NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm Allergy Drug Targets 2006, 5:121-131. 10.2174/187152806776383161, 16613571.
61. Fiorucci S, Santucci L, Distrutti E. NSAIDs, coxibs, CINOD and H2S-releasingNSAIDs: what lies beyond the horizon. Digest and Liv Dis 2007, 39:1043-1051.
62. Ajmone-Cat MA, Nicolini A, Minghetti L. Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and nitric oxide-releasing derivative, nitroflurbiprofen, on prostaglandin E(2), interleukin-1beta, and nitric oxide synthesis by activated microglia. J Neurosci Res 2001, 66:715-722. 10.1002/jnr.10038, 11746392.
63. Bernardo A, Ajmone-Cat MA, Gasparini L, Ongini E, Minghetti L. Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. J Neurochem 2005, 92:895-903. 10.1111/j.1471-4159.2004.02932.x, 15686492.
64. Idris A, Ralston SH, van't Hof RJ. The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. Eur J Pharmacol 2009, 602:215-222. 10.1016/j.ejphar.2008.11.023, 19046964.
65. Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002, 137:295-340. 10.1038/sj.bjp.0704876, 1573498, 12237248.
66. Furlan R, Kurne A, Bergami A, Brambilla E, Maucci R, Gasparini L, Butti E, Comi G, Ongini E, Martino G. A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol 2004, 150:10-9. 10.1016/j.jneuroim.2004.01.004, 15081244.
67. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. Neurodegeneration 1995, 4:257-69. 10.1016/1055-8330(95)90015-2, 8581558.
68. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-48. 10.1016/S0306-4522(96)00545-3, 9130785.
69. Jackson-Lewis V, Przedborski S. Protocol for the MPTP model of Parkinson's disease. Nature Protocols 2007, 2:141-151. 10.1038/nprot.2006.342, 17401348.
70. Aldini G, Carini M, Orioli M, Maffei Facino R, Wenk GL. Metabolic profile of NO-flurbiprofen (HCT1026) in rat brain and plasma: an LC-MS study. Life Sci 2002, 71:1487-1500. 10.1016/S0024-3205(02)01915-X, 12127904.
71. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-75.
72. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. Academic Press Inc 1997,
73. Baquet ZC, Williams D, Brody J, Smeyne RJ. A comparison of model-basaed (2D) and design-based (3D) stereological methods for estimating cell number in the subtantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 2009, 161:1082-1090. 10.1016/j.neuroscience.2009.04.031, 2705113, 19376196.
74. Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 1946, 94:239-247. 10.1002/ar.1090940210, 21015608.
75. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-8. 10.1016/0166-2236(96)10049-7, 8843599.
76. Gainetdinov RR, Fumagalli F, Joness SR, Caron MG. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997, 69:1322-1325. 10.1046/j.1471-4159.1997.69031322.x, 9282960.
77. Ho A, Blum M. Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J Neurosci 1998, 18:5614-29.
78. Date I, Felten DL, Felten SY. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res 1990, 519:266-76. 10.1016/0006-8993(90)90088-S, 1975765.
79. Sedelis M, Schwarting RKW, Husto JP. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125:109-122. 10.1016/S0166-4328(01)00309-6, 11682102.
80. Alvarez-Fisher D, Henze C, Strenzke C, Westrich J, Ferger B, Holinger GU, Oertel WH, Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice. Exp Neurol 2007, 210:182-193. 10.1016/j.expneurol.2007.10.012, 18053987.
81. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008, 131:1880-94. 10.1093/brain/awn101, 2442423, 18504291.
82. Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 2009, 87:1913-1921. 10.1002/jnr.22012, 2692550, 19224579.
83. Pierre SR, Lemmens MAM, Figueiredo-Pereira ME. Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J of Neuroinflammation 2009, 6:18.
84. Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci 1997, 811:60-67. 10.1111/j.1749-6632.1997.tb51989.x, 9186585.
85. Ritter JM, Harding I, Warren JB. Precaution, cyclooxygenase inhibition and cardiovascular risk. Trends in Pharmacol Sci 2009, 30:503-508.
86. Prosperi C, Scali C, Pepeu G, Casamenti F. NO-flurbiprofen attenuates excitotoxin-induced brain inflammation, and releases nitric oxide in the brain. Jpn J Pharmacol 2001, 86:230-5. 10.1254/jjp.86.230, 11459126.
87. Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GRJ. NO-flurbiprofen reduces amyloid β, is neuroprotective in cell culture, and anhances cognition in responce to cholinergic blockade. J Neurochem 2009, 111:766-776. 10.1111/j.1471-4159.2009.06353.x, 2792633, 19702655.
88. Bezard E, Jaber M, Gonon F, Boireau A, Bloch B, Gross CE. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur J Neurosci 2000, 8:2892-900.
89. Collier TJ, Lipton J, Dalkey BF, Palfi S, Chu Y, Sortwell C, Bakai RAE, Sladek JR, Kordower JJH. Aging related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 2007, 26:56-65. 10.1016/j.nbd.2006.11.013, 1899875, 17254792.
90. Przybylkowski A, Przybylkowski A, Kurkowska-Jastrzebska I. Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Res 2004, 1019:144-151. 10.1016/j.brainres.2004.05.095, 15306248.
91. Kaanan NM, Kordower JH, Collier TJ. Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration. Eur J Neurosci 2008, 27:3205-3215. 10.1111/j.1460-9568.2008.06307.x, 18598263.
92. Gasparini L, Ongini E, Wilcock D, Morgan D. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev 2005, 48:400-8. 10.1016/j.brainresrev.2004.12.029, 15850679.
93. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Perrotta C, Monopoli A, Sanvito F, Bottinelli R, Ongini E, Cossu G, Clementi E. Nitric oxide release combined with non-steroisal anti-inflammatory activity prevents muscular distrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci 2007, 104:264-269. 10.1073/pnas.0608277104, 1765447, 17182743.
94. Clancy R, Varenika B, Huang W, Ballou L, Attur M, Amin AR, Abramson SB. Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. J Immunol 2000, 165:1582-7.
95. Colasanti M, Suzuki K. The dual personality of NO. Trends Pharmacol Sci 2000, 21:249-252. 10.1016/S0165-6147(00)01499-1, 10979862.
96. Guastadisegni C, Minghetti L, Nicolini A, Polazzi E, Ade P, Balduzzi M, Levi G. Prostaglandin E2 synthesis is differentially affected by reactive nitrogen intermediates in cultured rat microglia and RAW 264.7 cells. FEBS Lett 1997, 413:314-8. 10.1016/S0014-5793(97)00925-3, 9280304.
97. Guastadisegni C, Nicolini A, Balduzzi M, Ajmone-Cat MA, Minghetti L. Modulation of PGE(2) and TNFalpha by nitric oxide and LPS-activated RAW 264.7 cells. Cytokine 2002, 19:175-80. 10.1006/cyto.2002.1955, 12297110.
98. Rocchitta G, Migheli R, Mura MP, Grella G, Esposito G, Marchetti B, Miele E, Desole MS, Miele M, Serra P-A. Signaling pathways in the nitric oxide and iron-induced dopamine release in the striatum of freely mooving rats: role of extracellular Ca2+ and L-type Ca2+ channels. Brain Res 2005, 1047:18-29. 10.1016/j.brainres.2005.04.008, 15890318.
99. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003, 964:288-94. 10.1016/S0006-8993(02)04085-4, 12576189.
100. Sawada H, Hishida R, Hirata Y, Ono K, Suzuki H, Muramatsu S, Nakano I, Nagatsu T, Sawada M. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine. J Neurosci Res 2007, 85:1752-1761. 10.1002/jnr.21241, 17469135.
101. Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 2004, 1:14. 10.1186/1742-2094-1-14, 509427, 15285801.
102. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron 2009, 64:110-122. 10.1016/j.neuron.2009.08.039, 2834890, 19840553.
103. Sandhu JK, Gardaneh M, Iwasiow R, Lanthier P, Gangaraju S, Ribecco-Lutkiewicz M. Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiology of Disease 2009, 33:405-414. 10.1016/j.nbd.2008.11.016, 19118631.
104. Smeyne M, Goloubeva O, Smeyne RJ. Strain-dependent susceptibility to MPTP and MPTP(+)-induced parkinsonism is determined by glia. Glia 2001, 34:73-80. 10.1002/glia.1042, 11307156.